Comparison
Enfuvirtid vs. Goserelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
159519-65-0
65807-02-5
Molecular weight
4491.88 g/mol
1269.43 g/mol
Half-life
no data
4.2 h
Sequence
no data
pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azgly-NH2Mechanism of action
Enfuvirtid
Enfuvirtide binds the first heptad-repeat region (HR1) of the gp41 subunit of the HIV envelope protein. This prevents the conformational change required for fusion of the viral and cell membranes — the virus cannot enter the cell.
Goserelin
As a GnRH agonist, goserelin binds to the GnRH receptors of the pituitary gland. Initial stimulation transiently raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous receptor occupancy, however, the receptors become desensitized and down-regulated, which reduces LH and FSH secretion and consequently the production of testosterone or estrogen. This mechanistic relationship is documented in the pharmacological literature.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
4
of which in humans
1
4
Effects recorded
2
3
Open conflicts
0
1
Documented adverse events
1
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Enfuvirtid and Goserelin?
- Enfuvirtid is classified as "Research other", while Goserelin is classified as "Research other". Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. Goserelin: Goserelin is a synthetic decapeptide and an agonist of gonadotropin-releasing hormone (GnRH). The medical literature describes it as a hormonal agent that suppresses the release of sex hormones through sustained receptor stimulation. Regulatory-approved indications include prostate cancer, advanced breast cancer, endometriosis, and endometrial thinning, among others. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Enfuvirtid or Goserelin?
- The highest available evidence level is "Human RCT" for Enfuvirtid and "Human RCT" for Goserelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Enfuvirtid and Goserelin in Germany and the United States?
- Germany: Enfuvirtid — Prescription, Goserelin — Prescription. United States: Enfuvirtid — Prescription, Goserelin — Prescription. These are factual summaries with source and review date on the individual pages.